TheStreet upgraded shares of REGENXBIO (NASDAQ:RGNX) from a d+ rating to a c rating in a research report released on Monday, TheStreetRatingsTable reports.
Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded REGENXBIO from a hold rating to a sell rating in a research report on Tuesday, January 5th. Barclays lowered their price target on REGENXBIO from $88.00 to $79.00 and set an overweight rating on the stock in a report on Thursday, September 24th. SVB Leerink upped their price target on REGENXBIO from $34.00 to $37.00 and gave the stock a market perform rating in a research note on Wednesday, January 6th. Morgan Stanley reduced their price objective on shares of REGENXBIO from $55.00 to $51.00 and set an overweight rating on the stock in a research report on Wednesday, November 11th. Finally, BidaskClub upgraded shares of REGENXBIO from a buy rating to a strong-buy rating in a research report on Friday, December 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. REGENXBIO has a consensus rating of Buy and a consensus target price of $57.00.
Shares of NASDAQ:RGNX opened at $47.43 on Monday. The company has a market capitalization of $1.77 billion, a P/E ratio of -12.99 and a beta of 0.95. REGENXBIO has a 1-year low of $20.03 and a 1-year high of $54.97. The firm’s 50 day simple moving average is $43.11 and its two-hundred day simple moving average is $34.72.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $1.12. The firm had revenue of $98.91 million for the quarter, compared to the consensus estimate of $24.80 million. REGENXBIO had a negative net margin of 222.24% and a negative return on equity of 31.06%. The company’s revenue was up 572.9% on a year-over-year basis. During the same period last year, the firm earned ($0.94) EPS. As a group, research analysts expect that REGENXBIO will post -2.97 EPS for the current year.
In related news, insider Patrick J. Christmas sold 10,122 shares of the stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $49.08, for a total value of $496,787.76. Following the completion of the transaction, the insider now owns 26,372 shares of the company’s stock, valued at approximately $1,294,337.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Vittal Vasista sold 21,124 shares of REGENXBIO stock in a transaction dated Wednesday, December 23rd. The stock was sold at an average price of $50.01, for a total value of $1,056,411.24. Following the completion of the transaction, the chief financial officer now owns 136,400 shares of the company’s stock, valued at approximately $6,821,364. The disclosure for this sale can be found here. Insiders have sold a total of 100,754 shares of company stock valued at $4,668,916 over the last quarter. Corporate insiders own 14.10% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Sofinnova Investments Inc. bought a new position in shares of REGENXBIO during the 3rd quarter valued at approximately $1,638,000. Principal Financial Group Inc. increased its position in REGENXBIO by 2.7% during the second quarter. Principal Financial Group Inc. now owns 249,925 shares of the biotechnology company’s stock valued at $9,205,000 after acquiring an additional 6,531 shares during the last quarter. Bank of America Corp DE raised its stake in shares of REGENXBIO by 442.6% in the second quarter. Bank of America Corp DE now owns 122,862 shares of the biotechnology company’s stock valued at $4,525,000 after acquiring an additional 100,220 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of REGENXBIO by 86.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,511 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 2,090 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of REGENXBIO by 106.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,715 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 1,400 shares during the last quarter. Hedge funds and other institutional investors own 77.45% of the company’s stock.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.